Načítá se...
Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series
Guidelines for the treatment of non-small cell lung cancer adenocarcinoma positive in epidermal growth factor mutations indicate tyrosine kinase inhibitors. There are currently three tyrosine kinase inhibitors that can be used as first line treatment: gefitinib, erlotinib and afatinib. Regarding erl...
Uloženo v:
| Vydáno v: | Respir Med Case Rep |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5458763/ https://ncbi.nlm.nih.gov/pubmed/28616379 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2017.05.013 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|